British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)

HIV Medicine

Volumn 15, Issue S4, 2014, Pages 1-77

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CESAREAN SECTION; DISEASE TRANSMISSION; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INFANT FEEDING; INFECTION PREVENTION; INFORMATION DISSEMINATION; LABORATORY TEST; MEMBRANE RUPTURE; MIXED INFECTION; PATIENT MONITORING; PATIENT PARTICIPATION; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; SCREENING; SOCIAL PSYCHOLOGY; UNITED KINGDOM; VAGINAL DELIVERY; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ARTIFICIAL MILK; DELIVERY; FEMALE; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; MALE; MEDICAL SOCIETY; NEWBORN; POST EXPOSURE PROPHYLAXIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION; UTILIZATION; VERTICAL TRANSMISSION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DELIVERY, OBSTETRIC; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; INFANT FORMULA; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MATERNAL HEALTH SERVICES; POST-EXPOSURE PROPHYLAXIS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; SOCIETIES, MEDICAL;

EID: 84908879909     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12185     Document Type: Article

References (366)

1. Health Protection Agency. HIV in the United Kingdom: 2012 report. London, Health Protection Services, Colindale, 2012. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317137200016 (accessed September 2013).
2. Health Protection Agency. Data tables of the unlinked anonymous dried blood spot survey of newborn infants - prevalence of HIV in women giving birth. Surveillance update. 2012. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287144874352 (accessed September 2013).
3. Duong T, Ades A, Gibb D etal. Vertical transmission rates for HIV on the British Isles: estimates based on surveillance data. BMJ 1999; 319: 1227-1229.
4. Townsend CL, Cortina-Borja M, Peckham CS etal. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22: 973-981.
5. Townsend C, Byrne L, Cortina-Borja M etal. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS 2014; 28: 1049-1057.
6. National Sudy of HIV in Pregnancy and Childhood. National surveillance data 2012. Available at: http://www.ucl.ac.uk/nshpc (accessed September 2013).
7. National Study of HIV in Pregnancy and Childhood. National surveillance data 2011. Available at: http://www.nshpn.ucl.ac.uk (accessed December 2011).
8. Judd A, Doerholt K, Tookey PA etal. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care. Clin Infect Dis 2007; 45: 918-924.
9. Lujan M, Burgos J, Gallego M etal. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis 2013; 57: 1722-1730.
10. Kenny J, Williams B, Prime K etal. Pregnancy outcomes in adolescents in the UK and Ireland growing up with HIV. HIV Med 2011; 13: 304-308.
11. Intercollegiate Working Party. Reducing Mother to Child Transmission of HIV Infection in the United Kingdom., Royal College of Paediatrics and Child Health, 2006. Available at: http://www.rcpch.ac.uk/publications/recent_publications/HIVreport.pdf (accessed May 2014).
12. Townsend C, Cliffe S, Tookey P. Uptake of antenatal HIV testing in the United Kingdom: 2000-2003. J Public Health 2006; 28: 248-252.
13. UK National Screening Committee. Infectious diseases in pregnancy screening programme: programme standards., 2010. Available at: http://infectiousdiseases.screening.nhs.uk/standards (accessed September 2013).
14. AIAU, NSHPC, CHIVA. Perinatal Transmission of HIV in England 2002-2005. 2007. Available at: http://www.ucl.ac.uk/nshpc/documents/perinatal-audit1/perinatal-audit1-execsummary (accessed September 2013).
15. Madge S, Phillips AN, Griffioen A etal. Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of women with HIV. Int J Epidemiol 1998; 27: 1068-1071.
16. Leroy V, De Clerq A, Ladner J etal. Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? A prospective cohort study from Kigali, Rwanda, 1992-1993. The pregnancy and HIV (EGE) Group. Genitourin Med 1995; 71: 207-211.
17. Health Protection Agency. Data tables of the unlinked anonymous dried blood spot survey of newborn infants- prevalence of HIV in women giving birth. Surveillance update. 2010. Available at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1287144874352 (accessed December 2011).
18. Low N, Sterne JAC, Barlow D. Inequalities in rates of gonorrhoea and chlamydia between black ethnic groups in south east London: cross sectional study. Sex Transm Infect 2001; 77: 15-20.
19. Chuachoowong R, Shaffer N, Siriwasin W etal. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 2000; 181: 99-106.
20. Hart C, Lennox J, Pratt-Palmore M etal. Correlation of human immunodeficiency virus type 1 RNA levels in blood and female genital tract. J Infect Dis 2000; 179: 871-882.
21. Fiore J, Suligoi B, Saracino A etal. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17: 169-176.
22. Kovacs A, Wasserman S, Burns D etal. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358: 1593-1601.
23. de Pasquale M, Leigh-Brown A, Cu-Uvin S etal. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: 37-44.
24. Warszawaski J, Tubiana R, Le Chenadec J etal. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22: 289-299.
25. Cameron D, Simonsen J, D'Costa L etal. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2: 403-407.
26. Dickerson M, Johnston J, Delea T etal. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria. Sex Transm Dis 1996; 23: 429-440.
27. Ghys P, Fransen K, Diallo M etal. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997; 11: F85-F93.
28. Lawn S, Subbarao S, Wright JT etal. Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis 2000; 181: 1950-1956.
29. Hashemi F, Ghassemi M, Roebuck K, Spear G. Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis. J Infect Dis 1999; 179: 924-930.
30. Hashemi F, Ghassemi M, Faro S etal. Induction of human immunodeficiency virus Type 1 expression by anaerobes associated with bacterial vaginosis. J Infect Dis 2000; 181: 1574-1580.
31. McClelland R, Wang C, Mandaliya K etal. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15: 105-110.
32. Cowan F, Humphrey J, Ntozini R etal. Maternal herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. AIDS 2008; 22: 193-201.
33. Bollen LJ, Whitehead SJ, Mock PA etal. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS 2008; 22: 1169-1176.
34. Ouedraogo A, Nagot N, Vergne L etal. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20: 2305-2313.
35. Patterson J, Hitti J, Selke S etal. Genital HSV detection among HIV-1-infected pregnant women in labor. Infect Dis Obstet Gynecol 2011; 2011: 157680.
36. Goldenberg RL, Hauth J, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000; 342: 1500-1507.
37. Hillier S, Martius J, Krohn M etal. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319: 972-978.
38. Landesman SH, Kalish LA, Burns DN etal. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med 1996; 334: 1617-1623.
39. Newell M, Dunn D, Peckham C etal. Vertical transmission of HIV-1: maternal immune status and obstetric factors: The European Collaborative Study. AIDS 1996; 10: 1675-1681.
40. Van Dyke R, Korber B, Popek E etal. The Ariel project: a prospective cohort study of Maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999; 179: 319-328.
41. Taha T, Brown E, Hoffman I etal. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 2006; 20: 1313-1321.
42. Hillier S, Nugent R, Eschenbach D etal. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995; 333: 1737-1742.
43. Taha TE, Gray RH. Genital tract infections and perinatal transmission of HIV. Ann NY Acad Sci 2000; 918: 84-98.
44. McDonald H, Brocklehurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2003; 2.
45. Varma R, Gupta J, James D, Kilby M. Do screening-preventative interventions in asymptomatic pregnancies reduce the risk of preterm delivery. A critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2006; 127: 145-159.
46. Farquhar C, Mbori-Ngacha D, Overbaugh J etal. Illness during pregnancy and bacterial vaginosis are associated with in-utero HIV-1 transmission. [Letter]. AIDS 2010; 24: 153-155.
47. McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2007: CD000262.
48. Fakoya A, Lamba H, Mackie N etal. UK guidelines for the management of sexual and reproductive health (SRH) of people living with HIV infection. HIV Med 2007; 9: 681-720.
49. Luesley D, Leeson S. Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme.Sheffield, NHS Cancer Screening Programmes, 2010. Available at: http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.pdf (accessed April 2012).
50. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Register International Interim Report for 1 January 1989 through 31 January 2013. 25 (1) ed. Wilmington, NC, USA, Registry Coordinating Center, 2013.
51. de Ruiter A, Mercey D, Anderson J etal. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9: 452-502.
52. Nightingale S. From the Food and Drug Administration. JAMA 1998; 280: 1472.
53. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Register International Interim Report for 1 January 1989 through 31 January 2011. Registry Coordinating Center, 2011. Available at: www.APRegistry.com (accessed April 2012).
54. Fundaro C, Genovese O, Rendeli C etal. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16: 299-300.
55. Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005; 25: 555-556.
56. Ekouevi DK, Coffie PA, Ouattara E etal. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2011; 56: 183-187.
57. Ford N, Mofenson L, Shubber Z etal. Safety of efavirenz in the first trimeser of pregnancy: an updated systematic review and meta-analysis. AIDS 2014; 28: S123-S131.
58. Brogly SB, Abzug MJ, Watts DH etal. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 2010; 29: 721-727.
59. Knapp KM, Brogly SB, Muenz DG etal. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2011: 164-170.
60. Joao EC, Calvet GA, Krauss MR etal. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 2010; 53: 176-185.
61. Townsend C, Willey B, Cortina-Borja M etal. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009; 23: 519-524.
62. Connor EM, Sperling RS, Gelber R etal. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-1180.
63. Tariq S, Townsend CL, Cortina-Borja M etal. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009. J Acquir Immune Defic Syndr 2011; 57: 326-333.
64. Tubiana R, Matheron S, Le Chenadec J etal. Extremely Low Risk of MTCT of HIV in Women Starting HAART before Pregnancy: French Perinatal Cohort, ANRS EPF CO1/11. 18th Conference on Retroviruses and Opportunistic Infections,. Boston, MA, USA. March 2011 [Abstract 735].
65. Lallemant M, Jourdain G, Ngo-Giang-Huong N etal. A Phase III Randomized, Partially Double-blind and Placebo-controlled Trial Comparing the Efficacy and Safety of Maternal and Infant NVP vs Infant only NVP, or Maternal LPV/r, in Addition to Standard ZDV Prophylaxis to Prevent Perinatal HIV Transmission: Thailand, PHPT-5. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. March 2011 [Abstract 741].
66. Important drug warning - Zerit and Videx. [Retyped letter from Bristol-Myers Squibb Company, dated 5 January 2001]. 2001. Available at: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm173947.htm (accessed May 2014).
67. Shapiro RL, Hughes MD, Ogwu A etal. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 2282-2294.
68. Study EC. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458-465.
69. Edwards S, Larbalestier N, Hay P etal. Experience of nevirapine use in a London cohort of HIV infected pregnant women. HIV Med 2001; 2: 89-91.
70. Natarajan U, Pym A, McDonald C etal. The safety of nevirapine in pregnancy. HIV Med 2007; 8: 64-69.
71. Ouyang DW, Brogly SB, Lu M etal. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS 2010; 24: 109-114.
72. Phanuphak N, Apornpong T, Intarasuk S etal. Toxicities from Nevirapine in HIV-infected males and females, including pregnant females with various CD4 cell counts. 12th Conference on Retroviruses and Opportunistic Infections. Boston, Ma, USA. February 2005 [Abstract 22].
73. Mirochnick M, Siminski S, Fenton T etal. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20: 803-805.
74. Mirochnick M, Fenton T, Gagnier P etal. Pharmacokinetics of nevirapine in human immunodeficiency virus type-1 infected pregnant women and their neonates. J Infect Dis 1998; 178: 368-374.
75. Taylor G, Lyall E, Back D etal. Pharmacological implications of prolonged in utero exposure to nevirapine. Lancet 2000; 355: 2134-2135.
76. Brooks Jackson J, Musoke P, Fleming T etal. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda:18 month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859-868.
77. Dabis F, Bequent L, Ekouevi D etal. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19: 309-318.
78. Lallemant M, Jourdain G, Le CS etal. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-228.
79. Ford N, Calmy A, Andrieux-Meyer I etal. Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. AIDS 2013; 27: 1135-1143.
80. de Vincenzi I, Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171-180.
81. Samuel M, Bradshaw D, Perry M etal. Atazanavir in pregnancy: a report of 155 cases. HIV Med 2011; 12.
82. van der Lugt J, Colbers A, Molto J etal. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther 2009; 14: 443-450.
83. Vithayasai V, Moyle G, Supajatura V etal. Safety and efficacy of saquinavir soft-gelatin capsules plus zidovudine plus optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Sydnr 2002; 30: 410-412.
84. Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44: 1647-1656.
85. Read PJ, Mandalia S, Khan P etal. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012; 26: 1095-1103.
86. Kay N, Fish R, Duncan S etal. The impact of HAART on HIV RNA decay during the first 2 weeks of therapy among HIV+ pregnant women. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA March 2012 [Abstract 1020].
87. Lorenzi P, Spicher V, Laubereau B etal. Antiretroviral therapies in pregnancy: maternal, foetal and neonatal effects. AIDS 1998; 12: F241-F247.
88. European Collaborative Study, Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-2930.
89. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380-387.
90. European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337-2339.
91. Townsend C, Cortina-Borja M, Peckham C, Tookey P. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-1026.
92. Tuomala RE, Shapiro DE, Mofenson LM etal. Antiretroviral Therapy during Pregnancy and the Risk of an Adverse Outcome. N Engl J Med 2002; 346: 1863-1870.
93. Tuomala R, Watts D, Li D etal. Improved Obstetric Outcomes and Few Maternal Toxicities Are Associated With Antiretroviral Therapy, Including Highly Active Antiretroviral Therapy During Pregnancy. J AIDS 2005; 38: 449-473.
94. Schulte J, Dominguez K, Sukalac T etal. Declines in Low Birth Weight and Preterm Birth Among Infants Who Were Born to HIV-Infected Women During an Era of Increased Use of Maternal Antiretroviral Drugs: Pediatric Spectrum of HIV Disease, 1989-2004. Pediatrics 2007; 119: e900-e906.
95. Cotter A, Garcia A, Duthely M etal. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193: 1195-1201.
96. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21: 607-615.
97. Beckerman K, Albano J, Cohan D etal. Exposure to combination antiretroviral (cARV) regimens containing protease inhibitors (PI) during pregnancy and prevalence of low birth weight/preterm delivery (LBW/PTD) among women with low pre-existing risk for LBW/PTD: a stratified analysis of 10, 082 pregnancies. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy. July 2011 [Abstract TULBPE018].
98. Machado ES, Hofer CB, Costa TT etal. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85: 82-87.
99. Martin F, Taylor G. Increased rates of pre-term delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single centre cohort study. J Infect Dis 2007; 196: 558-561.
100. Patel K, Shapiro D, Brogly S etal. Prenatal protease inhibitor use and risk of preterm birth among HIV-1 infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010; 201: 1035-1044.
101. Sibiude J, Warszawski J, Tubiana R etal. Large Increase in Prematurity between 1990 and 2009 in HIV-infected Women in the National ANRS French Perinatal Cohort: Does Ritonavir Boost Play a Role? 18th Conference on Retroviruses and Opportunistic Infections,. Boston, MA, USA. March 2011 [Abstract 743].
102. Hamilton B, Martin J, Ventura S. Births: preliminary data for 2010. Natl Vital Stat Rep 2011; 60: 1-26.
103. Powis KM, Kitch D, Ogwu A etal. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204: 506-514.
104. Cohan D, Natureeba P, Plenty A etal. No difference in risk of preterm birth among pregnant Ugandan women randomised to Lopinavir/ritonavir vs Efavirenz-based ART. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, Ga, USA March 2013 [Abstract LB183].
105. Roberts SS, Martinez M, Covington DL etal. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr 2009; 51: 456-461.
106. Perry M, Conway K, Flanagan S etal. Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacy and preterm delivery rates. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia. July 2013 [Abstract TUAC0101].
107. Rodman J, Flynn P, Robbins B etal. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type-1 infected women and newborn infants. J Infect Dis 1999: 1844-1850.
108. Odinecs A, Nosbich C, Keller R etal. In vivo maternal-fetal pharmacokinetics of stavudine (2', 3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996; 40: 196-202.
109. Moodley J, Moodley D, Pillay K etal. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-1333.
110. Best B, Mirochnick M, Capparelli E etal. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006; 20: 553-560.
111. Wang Y, Livingston E, Patil S etal. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus -infected women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180: 1536-1541.
112. Burchett S, Best B, Mirochnick M etal. Tenofovir pharmacokinetics during pregnancy, at delivery and post partum. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, Ca. February 2007 [Abstract 738b].
113. Colbers A, Hawkins D, Gingelmaier A etal. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1 infected pregnant women. AIDS 2013; 27: 739-748.
114. Benaboud S, Hirt D, Launay O etal. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother 2012; 56: 857-862.
115. Hirt D, Urien S, Ekouevi DK etal. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 2009; 85: 182-189.
116. Stek A, Best B, Luo W etal. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med 2011; 13: 226-235.
117. Cressey T, Stek A, Capparelli E etal. Efavirenz pharmacokinetics during the 3rd trimester of pregnancy and postpartum. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. March 2011 [Abstract 754].
118. Aweeka F, Stek A, Best B etal. Lopinavir protein binding in HIV-1 infected pregnant women. HIV Med 2010; 11: 232-238.
119. Best BM, Stek AM, Mirochnick M etal. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54: 381-388.
120. Else LJ, Douglas M, Dickinson L etal. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother 2012; 56: 816-824.
121. Lyons F, Lechelt M, de Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS 2007; 21: 1053-1054.
122. Acosta E, Bardeguez A, Zorrilla C etal. Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women. AntimicrobAgents Chemother 2004; 48: 430-436.
123. Ripamonti D, Cattaneo D, Maggiolo F etal. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21: 2409-2415.
124. Mirochnick M, Best BM, Stek AM etal. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56: 412-419.
125. Colbers A, Molto J, Ivanovic J etal. A comparison of the pharmacokinetics of darunavir, atazanavir and ritonavir during pregnancy and post-partum. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA March 2012.
126. Conradie F, Zorrilla C, Josipovic D etal. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med 2011; 12: 570-579.
127. Capparelli E, Best B, Stek A. Pharmacokinetics of darunavir once or twice daily during and after pregnancy. 3rd International Workshop on HIV Pediatrics Rome, Italy. July 2011 [Abstract P72].
128. Zorrilla C, Wright R, Osiyemi O etal. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100mg administered twice daily. HIV Med 2014; 15: 50-56.
129. Cespedes M, Ford S, Pakes G etal. Pharmacokinetics, cord blood concentrations, and tolerability of boosted fosamprenavir in pregnancy. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy. July 2011 [Abstract TUPE278].
130. Best B, Capparelli EV, Stek A. Raltegravir pharmacokinetics during pregnancy. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, Ma. September 2010 [Abstract H-1668a].
131. Colbers A, Molto J, Ivanovir J etal. A comparison of the pharmacokinetics of raltegravir during pregnancy and post-partum. 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, Fl, USA. April 2011
132. Ceccaldi PF, Ferreira C, Gavard L etal. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol 2008; 198: 433.e1-4332.
133. Peytavin G, Tubiana R, Ferreira C etal. Genital tract diffusion of different HIV PI in HIV-1 infected pregnant women. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, Ca, USA. February 2007 [Abstract 744].
134. Dumond J, Yeh R, Patterson K etal. First dose and steady-state genital tract pharmacokinetics of ten antiretroviral drugs in HIV-infected women: Implications for pre- and post- exposure prophylaxis. 13th Conference on Retroviruses and Opportunistic Infections. Denver, Co, USA. February 2006
135. Shaffer N, Chuachoowong R, Mock P etal. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773-780.
136. European Mode of Delivery Collaboration. Elective caesarian-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 1035-1039.
137. Lyall E, Blott M, de Ruiter A etal. Guidelines for the Management of HIV infection in pregnant women and the prevention of mother-to-child transmission. British HIV Association. HIV Med 2001; 2: 314-334.
138. Frenkel L, Wagner L, Demeter L etal. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995; 20: 1321-1326.
139. Kully C, Yerly S, Erb P etal. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study. J Infect Dis 1999; 179: 705-708.
140. Palumbo P, Holland B, Dobbs T etal. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001; 184: 1120-1126.
141. Welles SL, Pitt J, Colgrove RC etal. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000; 14: 263-271.
142. Eastman PS, Shapiro DE, Coombs RW etal. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J InfectDis 1998; 177: 557-564.
143. Ekpini R, Nkengasong J, Sibailly T etal. Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 2002; 16: 625-630.
144. Larbalestier N, Mullen J, O'Shea S etal. Drug Resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission. AIDS 2003; 17: 2665-2667.
145. Read P, Costelloe S, Mullen J etal. New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines. HIV Med 2008; 9: 448-451.
146. Olson S, Ngo-Giang-Huong N, Beck I etal. Zidovudine-resistance mutations detected by pyrosequencing in women treated with zidovudine monotherapy for PMTCT. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, USA March 2013 [Abstract].
147. Martin F, Navaratne L, Khan W etal. Pregnant women with HIV infection can expect healthy survival. J Acquir Immune Defic Sydnr 2006; 43: 186-192.
148. Markowitz M, Morales-Ramirez JO, Nguyen BY etal. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir mmune Defic Syndr 2006; 43: 509-515.
149. Murray JM, Emery S, Kelleher AD etal. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21: 2315-2321.
150. Cha A, Shaikh R, Williams S, Berkowitz LL. Rapid reduction in HIV viral load in late pregnancy with raltegravir: a case report. J Int Assoc Provid AIDS Care 2013; 12: 312-314.
151. Nobrega I, Travassos AG, Haguihara T etal. Short Communication: Use of Raltegravir in Late-Presenting HIV-Infected Pregnant Women. AIDS Res Hum Retroviruses 2013; 29: 1451-1454.
152. De Hoffer L, Di Biagio A, Bruzzone B etal. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. J Chemother 2013; 25: 181-183.
153. Westling K, Pettersson K, Kaldma A, Naver L. Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDS 2012; 26: 714-717.
154. Pinnetti C, Baroncelli S, Villani P etal. Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. J Antimicrob Chemother 2010; 65: 2050-2052.
155. Jeantils V, Messaouden H, Carbillon L. Pregnancy and a regimen containing raltegravir: a pilot study on the materno-foetal safety. 53rd International Conference on Antibiotics and Antimicrobial Chemotherapy. Denver, Co, USA. September 2013 [Abstract H-1463].
156. Musoke P, Guay LA, Bagenda D etal. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479-486.
157. McKeown DA, Rosenvinge M, Donaghy S etal. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010; 24: 2416-2418.
158. Wade NA, Birkhead GS, Warren BL etal. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New EnglJMed 1998; 339: 1409-1414.
159. Briand N, Warszawski J, Mandelbrot L etal. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? Clin Infect Dis 2013; 57: 903-914.
160. Hirt D, Ekouevi DK, Pruvost A etal. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob Agents Chemother 2011; 55: 2961-2967.
161. Walker BD. Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med 2007; 15: 134-136.
162. Ioannidis J, Abrams E, Ammann A etal. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001; 183: 539-545.
163. Rutland E, Mani R. Management of pregnancy in an HIV elite controller. Int J STD AIDS 2010; 21: 604-605.
164. McMahon DK, Zheng L, Hitti J etal. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clin Infect Dis 2013; 56: 1044-1051.
165. Sperling RS, Shapiro DE, Coombs RW etal. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Eng J Med 1996; 335: 1621-1629.
166. Watts DH, Lambert J, Stiehm ER etal. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003; 33: 585-593.
167. Melekhin VV, Shepherd BE, Jenkins CA etal. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. AIDS Patient Care STDS 2010; 24: 279-286.
168. Melo VH, Pinto JA, Freimanis-Hance L etal. Postpartum changes in plasma viral load and CD4 percentage among HIV-infected women from Latin American and Caribbean countries: the NISDI Perinatal Study. Mem Inst Oswaldo Cruz 2011; 106: 97-104.
169. Onen NF, Nurutdinova D, Sungkanuparph S etal. Effect of postpartum HIV treatment discontinuation on long-term maternal outcome. J Int Assoc Physicians AIDS Care (Chic) 2008; 7: 245-251.
170. Watts DH, Lu M, Thompson B etal. Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infect Dis Obstet Gynecol 2009; 2009: 456717.
171. El-Sadr WM, Lundgren JD, Neaton JD etal. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
172. Danel C, Moh R, Minga A etal. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367: 1981-1989.
173. Kitahata MM, Gange SJ, Abraham AG etal. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
174. Sterne JA, May M, Costagliola D etal. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
175. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2011: 1-167. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed December 2011).
176. Thompson MA, Aberg JA, Cahn P etal. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-333.
177. Bardeguez AD, Shapiro DE, Mofenson LM etal. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 2003; 32: 170-181.
178. Cohen MS, Chen YQ, McCauley M etal. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
179. Pogany K, van Valkengoed IG, Prins JM etal. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr 2007; 44: 395-400.
180. Ananworanich J, Gayet-Ageron A, Le BM etal. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368: 459-465.
181. Steingrover R, Pogany K, Fernandez GE etal. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008; 22: 1583-1588.
182. Palacios R, Senise J, Vaz M etal. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers. HIV Med 2009; 10: 157-162.
183. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577.
184. Rouet F, Chaix ML, Inwoley A etal. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004; 74: 34-40.
185. Konopnicki D, Mocroft A, DeWit S etal. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
186. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010; 14: e1024-e1031.
187. Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. Pediatrics 2003; 111: 1192-1197.
188. Lacombe K, Bottero J, Lemoine M etal. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 2010; 65: 10-17.
189. Tiribelli C, Rigato I. Liver cirrhosis and pregnancy. Ann Hepatol 2006; 5: 201.
190. Gibb DM, Kizito H, Russell EC etal. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9: e1001217.
191. Wilkins E, Nelson M, Agarwal K etal. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med 2013; 14: 1-71.
192. Brook G, Main J, Nelson M etal. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11: 1-30.
193. Schmutz G, Nelson M, Lutz T etal. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 1951-1954.
194. Matthews G. The management of HIV and hepatitis B coinfection. Curr Opin Infect Dis 2007; 20: 16-21.
195. Dore GJ, Cooper DA, Pozniak AL etal. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-1192.
196. Avihingsanon A, Lewin SR, Kerr S etal. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther 2010; 15: 917-922.
197. Matthews GV, Avihingsanon A, Lewin SR etal. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48: 1062-1069.
198. McGovern BH, Ditelberg JS, Taylor LE etal. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372.
199. Panel for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States (2010). 2011: 1-117. Available at: http://www.aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/ (accessed December 2011).
200. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007; 110: 941-955.
201. Xu WM, Cui YT, Wang L etal. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94-103.
202. Bellini C, Keiser O, Chave JP etal. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009; 10: 12-18.
203. Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus: a systematic review. Virol J 2008; 5: 100.
204. Shi Z, Yang Y, Ma L etal. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 147-159.
205. Public Health England. Hepatitis B: the green book, chapter 18. 2013. Available at: https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book (accessed September 2013).
206. Han G, Jiang H, Zhao W etal. Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission (VT) of chronic hepatitis B (CHB) in highly viremic mothers. The Liver Meeting San Francisco, Ca, USA. Nov 2011
207. Landes M, Newell ML, Barlow P etal. Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe. HIV Med 2008; 9: 526-534.
208. Thomas SL, Newell ML, Peckham CS etal. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27: 108-117.
209. Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis 2007; 44: 1123-1131.
210. Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol 2003; 32: 727-734.
211. Feikin DR, Elie CM, Goetz MB etal. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001; 20: 545-553.
212. Hershow RC, Riester KA, Lew J etal. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. J Infect Dis 1997; 176: 414-420.
213. Zanetti AR, Tanzi E, Romano L etal. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41: 208-212.
214. Ngo-Giang-Huong N, Jourdain G, Sirirungsi W etal. Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. Int J Infect Dis 2010; 14: e602-e607.
215. Mast EE, Hwang LY, Seto DS etal. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192: 1880-1889.
216. European Paediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192: 1872-1879.
217. England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis 2006; 6: 83-90.
218. Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA etal. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53: 1830-1838.
219. Mok J, Pembrey L, Tovo PA, Newell ML. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed 2005; 90: F156-F160.
220. Resti M, Azzari C, Mannelli F etal. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317: 437-441.
221. Roberts SS, Miller RK, Jones JK etal. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol 2010; 88: 551-559.
222. Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Hepatitis B vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev 2011: CD007879.
223. Sheffield JS, Hickman A, Tang J etal. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol 2011; 117: 1130-1135.
224. Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS 2013; 24: 117-122.
225. Geretti AM, Brook G, Cameron C etal. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795-848.
226. Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis. Arch Gynecol Obstet 2011; 283: 255-260.
227. Marine-Barjoan E, Berrebi A, Giordanengo V etal. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS 2007; 21: 1811-1815.
228. Simon A, Warszawski J, Kariyawasam D etal. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV infected mothers. JAMA 2011; 306: 70-78.
229. Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 2011; 25: 967-975.
230. Tural C, Fuster D, Tor J etal. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10: 118-125.
231. Qurishi N, Kreuzberg C, Luchters G etal. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713.
232. Fetal anomaly screening programme. 2011. Available at: http://www.screening.nhs.uk/fetalanomaly-scotland (accessed December 2011).
233. NICE. Antenatal care: routine care for the healthy pregnant woman. CG62. 2008. Available at: http://www.nice.org.uk/nicemedia/live/11947/40115/40115.pdf (accessed December 2011).
234. Nicolaides KH, Spencer K, Avgidou K etal. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226.
235. Gross S, Castillo W, Crane M etal. Maternal serum alpha-fetoprotein and human chorionic gonadotropin levels in women with human immunodeficiency virus. Am J Obstet Gynecol 2003; 188: 1052-1056.
236. Yudin MH, Prosen TL, Landers DV. Multiple-marker screening in human immunodeficiency virus-positive pregnant women: Screen positivity rates with the triple and quad screens. Am J Obstet Gynecol 2003; 189: 973-976.
237. Spencer K. First and second trimester markers of fetal aneuploidy in pregnant women with HIV infection. Fetal DiagnTher 2011; 29: 135-138.
238. Einstein F, Wright R, Trentacoste S etal. The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive. Am J Obstet Gynecol 2004; 191: 1004-1008.
239. Charlton TG, Franklin JM, Douglas M etal. The impact of HIV infection and antiretroviral therapy on the predicted risk of Down syndrome. PrenatDiagn 2013.
240. Savvidou MD, Samuel I, Syngelaki A etal. First-trimester markers of aneuploidy in women positive for HIV. Br J Obstet Gynecol 2011; 118: 844-848.
241. Mandelbrot L, Mayaux M, Bongain A, al e. Obstetric factors and mother to child transmission of human immunodeficiency virus type 1: the French perinatal cohort. Am J Obstet Gynecol 1996; 175: 661-667.
242. Mandelbrot L, Jasseron C, Ekoukou D etal. Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales French Perinatal Cohort. Am J Obstet Gynecol 2009; 200: 160-169.
243. Ekoukou D, Khuong-Josses MA, Ghibaudo N etal. Amniocentesis in pregnant HIV-infected patients. Absence of mother-to-child viral transmission in a series of selected patients. EurJ ObstetGynecolReprodBiol 2008; 140: 212-217.
244. Lopez M, Coll O. Chronic viral infections and invasive procedures: risk of vertical transmission and current recommendations. Fetal Diagn Ther 2010; 28: 1-8.
245. Holmes WR, Hofmeyr GJ. Management of breech presentation in areas with high prevalence of HIV infection. Int J Gynaecol Obstet 2004; 87: 272-276.
246. Owens M, Bhullar A, Carlan SJ etal. Effect of fundal pressure on maternal to fetal microtransfusion at the time of cesarean delivery. J Obstet Gynaecol Res 2003; 29: 152-156.
247. Boer K, Nellen J, Patel D etal. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. Br J Obstet Gynaecol 2007; 114: 148-155.
248. Boer K, England K, Godfried MH, Thorne C. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010; 11: 368-378.
249. Maiques V, Garcia-Tejedor A, Perales A, Navarro C. Intrapartum fetal invasive procedures and perinatal transmission of HIV. Eur J Obstet Gynecol Reprod Biol 1999; 87: 63-67.
250. Kind C, Rudin C, Siegrist C-A etal. Prevention of vertical transmission: additive protective effect of elective caesarean section and zidovudine prophylaxis. AIDS 1998: 205-210.
251. NICE. Intrapartum care. CG55. 2007. Available at: http://www.nice.org.uk/guidance/CG55/NICEGuidance (accessed December 2011).
252. Tuomala RE, O'Driscoll PT, Bremer JW etal. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003; 187: 375-384.
253. Cu-Uvin S, DeLong AK, Venkatesh KK etal. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24: 2489-2497.
254. Neely MN, Benning L, Xu J etal. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44: 38-42.
255. NICE. Caesarian section. CG132. 2011. Available at: http://www.nice.org.uk/CG132 (accessed December 2011).
256. International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977-987.
257. Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005: CD005479.
258. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006. Br J Obstet Gynecol 2008; 115: 1078-1086.
259. Cavasin H, Dola T, Uribe O etal. Postoperative infectious morbidities of cesarean delivery in human immunodeficiency virus-infected women. Infect Dis Obstet Gynecol 2009; 2009: 827405.
260. Parisaei M, Anderson J, Erskine K, Gann S. Experience of delivering women with HIV in an inner city London hospital 1994-2004. Int J STD AIDS 2007; 18: 527-530.
261. Morrison J, Rennie J, Milton P. Neonatal respiratory morbidity and mode of delivery at term:influence of timing of elective caesaren section. Br J Obstet Gynaecol 1995; 102: 101-106.
262. Minkoff H, Burns DN, Landesman S etal. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995; 173: 585-589.
263. International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15: 357-368.
264. Garcia-Tejedor A, Perales A, Maiques V. Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet 2003; 82: 17-23.
265. Haile-Selassie H, Masters J, de Ruiter A, Tookey P. Duration of ruptured membranes and vertical transmission of HIV: data from national surveillance in the UK and Ireland. 2011. Available at: http://www.chiva.org.uk/professionals/health/events/previous/conference11/index.html (accessed May 2014).
266. Cotter AM, Brookfield KF, Duthely LM etal. Duration of membrane rupture and risk of perinatal transmission of HIV-1 in the era of combination antiretroviral therapy. Am J Obstet Gynecol 2012; 207: 482-485.
267. Chi BH, Mudenda V, Levy J etal. Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. Am J Obstet Gynecol 2006; 194: 174-181.
268. Mofenson LM, Lambert JS, Stiehm ER etal. Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in women treated with Zidovudine. N Engl J Med 1999; 341: 385-393.
269. Wabwire-Mangen F, Gray RH, Mmiro FA etal. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr 1999; 22: 379-385.
270. NICE. Induction of labour. CG70. 2008. Available at: http://www.nice.org.uk/CG70 (accessed December 2011).
271. Brookfield K, Dutherly L, Cotter A. Rupture of membranes greater than four hours is not a risk factor for perinatal HIV transmission in the era of combination antiretroviral therapy. Am J Obstet Gynecol 2011; 204(Suppl 1): S42-S43.
272. Royal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality: Royal College Greentop Guideline 7. 2010. Available at: http://www.rcog.org.uk/files/rcog-corp/GTG%207.pdf (accessed December 2011).
273. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2010: CD001058.
274. Frenkel LM, Cowles MK, Shapiro DE etal. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175: 971-974.
275. Bhadrakom C, Simonds RJ, Mei JV etal. Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 2000; 14: 509-516.
276. Colgrove RC, Pitt J, Chung PH etal. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998; 12: 2281-2288.
277. Masquelier B, Chaix M, Burgard M etal. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Sydnr 2001; 27: 99-104.
278. Nielsen-Saines K, Watts H, Goncalces Veloso V etal. Phase III Randomized Trial of the Safety and Efficacy of 3 Neonatal ARV Regimens for Prevention of Intrapartum HIV-1 Transmission: NICHD HPTN 040/PACTG 1043. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA. March 2011 [Abstract 124LB].
279. Taha T, Kumwenda N, Gibbons A etal. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission on HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362: 1171-1177.
280. Moodley D, Moodley J, Coovadia H etal. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-735.
281. Taha TE, Kumwenda NI, Hoover DR etal. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292: 202-209.
282. Haile-Selassie H, Townsend C, Tookey P. Use of neonatal post-exposure prophylaxis for prevention of mother-to-child HIV transmission in the UK and Ireland. HIV Med 2011; 12: 422-427.
283. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C etal. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-2093.
284. Boucher F, Modlin J, Weller S etal. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137-144.
285. Mirochnick M, Nielsen-Saines K, Pilotto JH etal. Nelfinavir and Lamivudine Pharmacokinetics During the First Two Weeks of Life. Pediatr Infect Dis J 2011; 30: 769-772.
286. Tremoulet AH, Capparelli EV, Patel P etal. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother 2007; 51: 4297-4302.
287. Hirt D, Urien S, Rey E etal. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2009; 53: 1067-1073.
288. Jullien V, Urien S, Chappuy H etal. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. J Clin Pharmacol 2005; 45: 257-264.
289. Benaboud S, Ekouevi DK, Urien S etal. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2011; 55: 331-337.
290. Mirochnick M, Dorenbaum A, Blanchard S etal. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Sydnr 2003; 33: 153-156.
291. Mirochnick M, Nielsen-Saines K, Pilotto JH etal. Nevirapine concentrations in newborns receiving an extended prophylactic regimen. J Acquir Immune Defic Syndr 2008; 47: 334-337.
292. Chadwick EG, Capparelli EV, Yogev R etal. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008; 22: 249-255.
293. Chadwick EG, Yogev R, Alvero CG etal. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS 2011; 25: 643-649.
294. Chadwick EG, Pinto J, Yogev R etal. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. PediatrInfect Dis J 2009; 28: 215-219.
295. Urien S, Firtion G, Anderson ST etal. Lopinavir/ritonavir population pharmacokinetics in neonates and infants. Br J Clin Pharmacol 2011; 71: 956-960.
296. Anon. FDA Drug Safety Communication: Serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm#.Tu-NUvkx9yw.email (accessed 12/19/2011).
297. Vankandondera J, Luchters S, Hassink E etal. Reducing risk of HIV-1 Transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA). 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France. July 2003
298. Capparelli EV, Mirochnick M, Dankner WM etal. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142: 47-52.
299. Wiznia A, Church J, Emmanuel P etal. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007; 26: 799-805.
300. Zhang X, Nieforth K, Lang JM etal. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002; 72: 10-19.
301. Desfrere L, de O, I, Goffinet F etal. Increased incidence of necrotizing enterocolitis in premature infants born to HIV-positive mothers. AIDS 2005; 19: 1487-1493.
302. Van Rompay KK, Otsyula MG, Marthas ML etal. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995; 39: 125-131.
303. Tsai CC, Emau P, Follis KE etal. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 4265-4273.
304. Bottiger D, Johansson NG, Samuelsson B etal. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997; 11: 157-162.
305. Ferguson W, Goode M, Walsh A etal. Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting. Pediatr Infect Dis J 2011; 30: 408-412.
306. Lahoz R, Noguera A, Rovira N etal. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr Infect Dis J 2010; 29: 376-379.
307. Lallemant M, Jourdain G, Le Coeur S etal. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type I. New Engl J Med 2000; 343: 982-991.
308. Department of Health. Hepatitis B. Immunisation against infectious disease. 2006 ed. London, Department of Health, 2007: 161-184.
309. Coutsoudis A, Dabis F, Fawzi W etal. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189: 2154-2166.
310. Dunn D, Newell M-L, Ades A, Peckham C. Estimates of the risk of HIV-1 transmission through breastfeeding. Lancet 1992; 340: 585-588.
311. Nduati R, Richardson BA, John G etal. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001; 357: 1651-1655.
312. Read J, Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189: 2154-2166.
313. Nduati R, John G, Mbori-Ngacha D etal. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283: 1167-1174.
314. Taylor G, Anderson J, Clayden P etal. British HIV Association and Children's HIV Association position statement on infant feeding in the UK 2011. HIV Med 2011; 12: 389-393.
315. World Health Organization. HIV and infant feeding: a guide for healthcare managers and supervisors.Geneva, WHO, 2003. Available at: http://www.who.int/nutrition/publications/HIV_IF_guide_for_healthcare.pdf (accessed May 2014).
316. Homsy J, Moore D, Barasa A etal. Breastfeeding, mother-to-child HIV tansmission, and mortality among infants born to HIV-infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2009; 53: 28-35.
317. Kilewo C, Karlsson K, Ngarina M etal. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus Study. J Acquir Immune Defic Syndr 2009; 52: 406-416.
318. Marazzi MC, Nielsen-Saines K, Buonomo E etal. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J 2009; 28: 483-487.
319. Peltier CA, Ndayisaba GF, Lepage P etal. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009; 23: 2415-2423.
320. Chasela CS, Hudgens MG, Jamieson DJ etal. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. NEnglJ Med 2010; 362: 2271-2281.
321. Fawzy A, Arpadi S, Kankasa C etal. Early weaning increases diarrhea morbidity and mortality among uninfected children born to HIV-infected mothers in Zambia. I Infect Diseases 2011; 203: 1222-1230.
322. Kafulafala G, Hoover D, Taha T etal. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Sydnr 2010; 53: 6-13.
323. World Health Organization. Guidelines on HIV and Infant Feeding 2010: Principles and recommendations for infant feeding in the context of HIV and a summary of evidence. 2010. Available at: http://www.who.int/child_adolescent_health/documents/9789241599535/en/index.html (accessed May 2014).
324. Kilewo C, Karlsson K, Massawe A etal. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48: 315-323.
325. Shapiro RL, Ndung'u T, Lockman S etal. Highly Active Antiretroviral Therapy Started during Pregnancy or Postpartum Suppresses HIV-1 RNA, but Not DNA, in Breast Milk. J Infect Dis 2005; 192: 713-719.
326. Valea D, Tuaillon E, Al TY etal. CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. Retrovirology 2011; 8: 34.
327. House of Lords Select Committee on HIV and AIDS in the United Kingdom. No vaccine, no cure: HIV and AIDS in the United Kingdom. 2011. Available at: http://www.publications.parliament.uk/pa/ld201012/ldselect/ldaids/188/188.pdf (accessed December 2011).
328. Coutsoudis A, Pillay K, Kuhn L etal. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15: 379-387.
329. Centers of Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001; 49: 1153-1156.
330. Lambert JS, Harris DR, Stiehm ER etal. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Sydnr 2003; 34: 512-519.
331. Burgard M, Blanche S, Jasseron C etal. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr 2012; 160: 60-66.
332. Burgard M, Blanche S, Mayaux MJ etal. Impact of neonatal prophylaxis on early diagnosis in newborns. 10th Conference on Retroviruses and Opportunistic Infections. San Francisco, Ca. Februrary 2003
333. Nastouli E, Atkins M, Seery P etal. False-positive HIV antibody results with ultrasensitive serological assays in uninfected infants born to mothers with HIV. AIDS 2007; 21: 1222-1223.
334. Frange P, Burgard M, Lachassinne E etal. Late postnatal HIV infection in children born to HIV-1-infected mothers in a high-income country. AIDS 2010; 24: 1771-1776.
335. Department of Health. Children's HIV National Network (CHINN) Review 2005. London, Department of Health, 2006. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4139815.pdf (accessed December 2011).
336. Ezeanochie MC, Olagbuji BN, Ande AB etal. Prevalence and correlates of intimate partner violence against HIV-seropositive pregnant women in a Nigerian population. Acta Obstet Gynecol Scand 2011; 90: 535-539.
337. Shamu S, Abrahams N, Zarowsky C etal. Intimate partner violence during pregnancy in Zimbabwe: a cross-sectional study of prevalence, predictors and associations with HIV. Trop Med Int Health 2013; 18: 696-711.
338. Dhairyawan R, Tariq S, Scourse R, Coyle K. Intimate partner violence in women living with HIV attending an inner city clinic in the United Kingdom: Prevalence and associated factors. HIV Med 2013; 14: 303-310.
339. Wood C, Kumalo P, Ainsworth J etal. Disclosure, discordance and decisions: the psychosocial impact of antenatal HIV testing. 6th International Congress On Drug Therapy in HIV Infection. Glasgow, UK. November 2002 [Abstract P319].
340. Wood C, Ellison G. What have clinicians learnt from working with HIV/AIDS? A medical perspective from London. In: Ellison G, Parker M, Campbell C, eds. Learning from HIV/AIDS. Cambridge, Cambridge University Press, 2003: 105-137.
341. Siriwasin W, Shaffer N, Roongpisuthipong A etal. HIV prevalence, risk, and partner serodiscordance among pregnant women in Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group. JAMA 1998; 280: 49-54.
342. Guilen A, Fogarty L, O'Campo P etal. Women living with HIV: disclosure, violence, and social support. J Urban Health 2000; 77: 480-491.
343. Stein M, Freedberg K, Sullivan L etal. Sexual Ethics. Disclosure of HIV Positive status to partners. Archives of Internal Medicine, 1998, Feb 9;158(3):253-7. Arch Intern Med 1998; 158: 253-257.
344. WHO Department of Gender WaH, WHO Cluster of Family and Community Health. Gender dimensions of HIV status disclosure to sexual partners: Rates, barriers and outcomes for women.Geneva, 2003. Available at: http://www.who.int/gender/documents/women_and_girls/9241590734/en/ (accessed December 2011).
345. Council GM. Confidentiality: disclosing information about serious communicable diseases. 2009. Available at: http://www.gmc-uk.org/Confidentiality_disclosing_info_serious_commun_diseases_2009.pdf_27493404.pdf (accessed December 2011).
346. Serovich JM. Helping HIV-positive persons to negotiate the disclosure process to partners, family members, and friends. J Marital FamTher 2000; 26: 365-372.
347. Freeman E, Glynn J, for the Study Group on Heterogeneity of HIV epidemics in African Cities. Factors affecting HIV concordancy in married couples in four African cities. AIDS 2004; 18: 1715-1720.
348. Benn P, Fisher M, Kulasegaram R. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). Int J STD AIDS 2011; 22: 695-708.
349. General Health Protection/Department of Health. HIV and Infant Feeding: Guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS. Department of Health Publications, 2004. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4089892 (accessed 12/22/2011).
350. Creighton S, Sethi G, Edwards SG, Miller R. Dispersal of HIV positive asylum seekers: national survey of UK healthcare providers. BMJ 2004; 329: 322-323.
351. National AIDS Trust, British HIV Association. The dispersal process for ssylum seekers living with HIV. Advice for health care and voluntary sector professionals. 2006. Available at: http://www.nat.org.uk/Media%20Library/Files/PDF%20documents/NAT-Dispersal-Process-For-Asylum-Seekers.pdf (accessed December 2011).
352. National AIDS Trust, British HIV Association. Detention, removal and people living with HIV. Advice for health care and voluntary sector professionals. 2009. Available at: http://www.nat.org.uk/Media%20library/Files/Policy/Poverty%20and%20Social%20Disadvantage/NAT%20and%20BHIVA%20Booklet%20on%20HIV%20and%20Removal%20Centres%20(June%202009)%20EMAIL-1.pdf (accessed December 2011).
353. British HIV Association, Children's HIV Association, British Association for Sexual Health and HIV. Don't forget the children: Guidance for the HIV testing of children with HIV positive parents. 2009. Available at: http://www.chiva.org.uk/files/guidelines/dont-forget.pdf (accessed December 2011).
354. British Psychological Society, British HIV Association, Medical Foundation for AIDS & Sexual Health. Standards for psychological support of adults living with HIV. 2011. Available at: http://www.bhiva.org/StandardsForPsychologicalSupport.aspx http://www.bhiva.org/documents/Publications/Standards_for_psychological_support_for_adults_living_with_HIV.pdf (accessed December 2011).
355. NICE. Antenatal and postnatal mental health. CG45. 2007. Available at: http://guidance.nice.org.uk/CG45/NICEGuidance/pdf/English (accessed December 2011).
356. Moodley D, Pillay K, Naidoo K etal. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol 2001; 41: 732-741.
357. Frasca K, Fisher RG, McGuire E. Alternative dosage of zidovudine in infants exposed to maternal human immunodeficiency virus infection. Pediatr Infect Dis J 2009; 28: 1131-1132.
358. Durand-Gasselin L, Pruvost A, Dehee A etal. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob Agents Chemother 2008; 52: 2555-2563.
359. Hirt D, Pruvost A, Ekouevi DK etal. Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). Antimicrob Agents Chemother 2011; 55: 2953-2960.
360. Shetty A, Coovadia H, Mirochnick M etal. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2004; 34: 482-490.
361. Jullien V, Urien S, Hirt D etal. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006; 50: 3548-3555.
362. Verweel G, Burger DM, Sheehan NL etal. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther 2007; 12: 453-458.
363. Simonds RJ, Lindegren ML, Thomas P etal. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. N Engl J Med 1995; 332: 786-790.
364. th September 2011. Available at www.bhiva.org (accessed April 2012).
365. Guyatt GH, Oxman AD, Kunz R etal. Going from evidence to recommendations. BMJ 2008; 336: 1049-1051.
366. The Grading of Recommendations Assessment, Development and Evaluation (short GRADE) Working Group. Available at www.gradeworkinggroup.org (accessed April 2012).